Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 27;8(26):43506-43520.
doi: 10.18632/oncotarget.16490.

The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis

Futao Zhou  1 , Danli Wang  1
Affiliations
Review

The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis

Futao Zhou et al. Oncotarget. .

Abstract

Published studies revealed that the microtubule-associated protein tau (MAPT) gene polymorphisms increased Alzheimer's disease (AD) risk; the associations of 4 single nucleotide polymorphisms (SNPs, rs242557G/A, rs2471738C/T, rs3785883G/A and rs1467967A/G) of the MAPT gene with AD risk, however, remain inconclusive. Here, we conducted a meta-analysis to investigate the relationship between the MAPT SNPs and AD risk. A significant association of SNP rs242557 with AD risk was found in a dominant [odds ratio (OR) = 1.05, 95% confidence interval (CI) = 1.01, 1.10, P = 0.025] genetic model, and a suggestive association in an allelic (OR = 1.03, 95% CI = 1.00, 1.06, P = 0.078). When APOE epsilon 4 carrier status was included in stratified analysis, this association was even stronger (allelic model for the APOE epsilon 4 positive individuals: OR = 1.24, 95% CI = 1.08, 1.43, P = 0.003). Furthermore, a significant association of SNP rs2471738 with AD risk was found under all the four models (allelic: OR = 1.11, 95% CI = 1.01, 1.20, P = 0.021; dominant: OR = 1.10, 95% CI = 1.00, 1.21, P = 0.046; recessive: OR = 1.18, 95% CI = 1.05, 1.32, P = 0.004; additive: OR = 1.20, 95% CI = 1.07, 1.34, P = 0.002) models. However, pooled results suggest that the neither rs3785883 nor rs1467967 is associated with AD risk under all the four genetic models. In summary, our study provides further evidence of the associations of the MAPT SNPs with AD risk.

Keywords: Alzheimer’s disease; meta-analysis; microtubule-associated protein tau; single nucleotide polymorphisms.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interests.

Figures

Figure 1
Figure 1. Flow diagram of study selection
Figure 2
Figure 2. Forest plot for the meta-analysis of the association of SNP rs242557 and AD risk under the allelic model (A vs. G)
Figure 3
Figure 3. Forest plot for the meta-analysis of the association of SNP rs242557 and AD risk under the dominant model (AA + AG vs. GG)
Figure 4
Figure 4. Forest plot for the meta-analysis of the association of SNP rs242557 and AD risk stratified by APOE ε4 allele status
Figure 5
Figure 5. Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the allelic model (T vs. C)
Figure 6
Figure 6. Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the dominant model (TT + TC vs. CC)
Figure 7
Figure 7. Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the recessive model (TT vs. CC + TC)
Figure 8
Figure 8. Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the additive model (TT vs. CC)
Figure 9
Figure 9. Forest plot for the meta-analysis of the association of SNP rs3785883 and AD risk under the allelic model (A vs. G)
Figure 10
Figure 10. Forest plot for the meta-analysis of the association of SNP rs1467967 and AD risk under the allelic model (G vs. A)
Figure 11
Figure 11. Sensitivity analysis for rs242557 A. and rs2471738 B. under the allelic model
Figure 12
Figure 12. Sensitivity analysis for rs3785883 A. and rs1467967 B. under the allelic model
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Preliminary exploration of the co-regulation of Alzheimer's disease pathogenic genes by microRNAs and transcription factors.
    Zhang Q, Yang P, Pang X, Guo W, Sun Y, Wei Y, Pang C. Zhang Q, et al. Front Aging Neurosci. 2022 Dec 6;14:1069606. doi: 10.3389/fnagi.2022.1069606. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36561136 Free PMC article.
  • Non-invasive and high-throughput interrogation of exon-specific isoform expression.
    Truong DJ, Phlairaharn T, Eßwein B, Gruber C, Tümen D, Baligács E, Armbrust N, Vaccaro FL, Lederer EM, Beck EM, Geilenkeuser J, Göppert S, Krumwiede L, Grätz C, Raffl G, Schwarz D, Zirngibl M, Živanić M, Beyer M, Körner JD, Santl T, Evsyukov V, Strauß T, Schwarz SC, Höglinger GU, Heutink P, Doll S, Conrad M, Giesert F, Wurst W, Westmeyer GG. Truong DJ, et al. Nat Cell Biol. 2021 Jun;23(6):652-663. doi: 10.1038/s41556-021-00678-x. Epub 2021 Jun 3. Nat Cell Biol. 2021. PMID: 34083785 Free PMC article.
  • Validation of Enhancer Regions in Primary Human Neural Progenitor Cells using Capture STARR-seq.
    Gaynor-Gillett SC, Cheng L, Shi M, Liu J, Wang G, Spector M, Flaherty M, Wall M, Hwang A, Gu M, Chen Z, Chen Y, Consortium P, Moran JR, Zhang J, Lee D, Gerstein M, Geschwind D, White KP. Gaynor-Gillett SC, et al. bioRxiv [Preprint]. 2024 Mar 18:2024.03.14.585066. doi: 10.1101/2024.03.14.585066. bioRxiv. 2024. Update in: Genome Res. 2025 Aug 1;35(8):1887-1901. doi: 10.1101/gr.279584.124. PMID: 38562832 Free PMC article. Updated. Preprint.
  • Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries.
    Gharahkhani P, Jorgenson E, Hysi P, Khawaja AP, Pendergrass S, Han X, Ong JS, Hewitt AW, Segrè AV, Rouhana JM, Hamel AR, Igo RP Jr, Choquet H, Qassim A, Josyula NS, Cooke Bailey JN, Bonnemaijer PWM, Iglesias A, Siggs OM, Young TL, Vitart V, Thiadens AAHJ, Karjalainen J, Uebe S, Melles RB, Nair KS, Luben R, Simcoe M, Amersinghe N, Cree AJ, Hohn R, Poplawski A, Chen LJ, Rong SS, Aung T, Vithana EN; NEIGHBORHOOD consortium; ANZRAG consortium; Biobank Japan project; FinnGen study; UK Biobank Eye and Vision Consortium; GIGA study group; 23 and Me Research Team; Tamiya G, Shiga Y, Yamamoto M, Nakazawa T, Currant H, Birney E, Wang X, Auton A, Lupton MK, Martin NG, Ashaye A, Olawoye O, Williams SE, Akafo S, Ramsay M, Hashimoto K, Kamatani Y, Akiyama M, Momozawa Y, Foster PJ, Khaw PT, Morgan JE, Strouthidis NG, Kraft P, Kang JH, Pang CP, Pasutto F, Mitchell P, Lotery AJ, Palotie A, van Duijn C, Haines JL, Hammond C, Pasquale LR, Klaver CCW, Hauser M, Khor CC, Mackey DA, Kubo M, Cheng CY, Craig JE, MacGregor S, Wiggs JL. Gharahkhani P, et al. Nat Commun. 2021 Feb 24;12(1):1258. doi: 10.1038/s41467-020-20851-4. Nat Commun. 2021. PMID: 33627673 Free PMC article.
  • Potential common pathogenesis of several neurodegenerative diseases.
    Fan T, Peng J, Liang H, Chen W, Wang J, Xu R. Fan T, et al. Neural Regen Res. 2026 Mar 1;21(3):972-988. doi: 10.4103/NRR.NRR-D-24-01054. Epub 2025 May 30. Neural Regen Res. 2026. PMID: 40522761 Free PMC article.
See all "Cited by" articles

References

    1. Giacobini E, Gold G. Alzheimer disease therapy—moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9:677–686. - PubMed
    1. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer’s disease. The Lancet. 2016;388:505–517. - PubMed
    1. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–622. - PubMed
    1. Liu QY, Yu JT, Miao D, Ma XY, Wang HF, Wang W, Tan L. An exploratory study on STX6, MOBP, MAPT, and EIF2AK3 and late-onset Alzheimer's disease. Neurobiol Aging. 2013;34:1513–1519. - PubMed
    1. Laws SM, Friedrich P, Diehl-Schmid J, Muller J, Eisele T, Bauml J, Forstl H, Kurz A, Riemenschneider M. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer’s disease. Mol Psychiatry. 2007;12:510–517. - PubMed